65 results on '"Collen, Desire"'
Search Results
2. Emerging treatments for thrombocytopenia: Increasing platelet production
3. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor
4. Genetic evidence for a tumor suppressor role of HIF-2α
5. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells
6. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
7. Clinical development of PEGylated recombinant staphylokinase (PEG–Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction
8. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo
9. Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia
10. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model
11. Depletion of circulating α2-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization
12. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes
13. Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS)
14. Circulating Activated Platelets Assist THP-1 Monocytoid/Endothelial Cell Interaction Under Shear Stress
15. Structure-Function Analyses of Thrombomodulin by Gene-Targeting in Mice: The Cytoplasmic Domain Is Not Required for Normal Fetal Development
16. Involvement of Sp1 in basal and retinoic acid induced transcription of the human tissue-type plasminogen activator gene
17. Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity.
18. Development of Megakaryocyte-Specific Lentiviral Vectors for Gene Therapy of Platelet Disorders.
19. Role of Plasmin and uPAR in Bone Marrow HSC/HPC Retention and Mobilization.
20. Critical Amplification by Gas6 of the Epo-Dependent Erythropoietic Response to Anemia: Novel Opportunities for Anemia Treatment.
21. Novel Role of Plasmin in Mobilization and of uPAR in Retention of Hematopoietic Stem/Progenitor Cells in the Bone Marrow Niche: Therapeutic Implications.
22. Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial ischemia-reperfusion injury in pigs
23. Survivin does not inhibit caspase-3 activity
24. Circulating oxidized LDL and the assessment of cardiovascular risk
25. Increased levels of oxidized LDL in obese patients are normalised by treatment with atorvastatin
26. On the molecular interactions between plasminogen-staphylokinase, α 2-antiplasmin-formula> and fibrin
27. Physicochemical, immunochemical and functional comparison of human histidine-rich glycoprotein and autorosette inhibition factor
28. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26
29. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1)
30. Nonisotopic Quantitative Analysis of Protein–DNA Interactions at Equilibrium
31. Genetic Analysis of Blood Vessel Formation: Role of Endothelial Versus Smooth Muscle Cells
32. Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals
33. On the role of coagulation and fibrinolysis in atherosclerosis
34. 10 New thrombolytic agents and strategies
35. 1 Mechanisms of physiological fibrinolysis
36. Activation of the Fibrinolytic System
37. Vascular development and disorders: Molecular analysis and pathogenic insights
38. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
39. Endothelium in hemostasis and thrombosis
40. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis
41. A Functional Assay of Protein C in Human Plasma
42. Adenovirus-Mediated Transfer of Tissue-Type Plasminogen Activator Augments Thrombolysis in Tissue-Type Plasminogen Activator–Deficient and Plasminogen Activator Inhibitor-1–Overexpressing Mice
43. Thrombolytic Therapy in the Eighties
44. Pharmacokinetic and Thrombolytic Properties of Chimeric Plasminogen Activators Consisting of a Single-Chain Fv Fragment of a Fibrin-Specific Antibody Fused to Single-Chain Urokinase
45. Comparative Thrombolytic Properties of Single-Chain Forms of Urokinase-Type Plasminogen Activator
46. Plasminogen Receptors, Urokinase Receptors, and Their Modulation on Human Endothelial Cells
47. Antithrombotic Properties of L-Cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-Sulfoxide (G4120) in a Hamster Platelet-Rich Femoral Vein Thrombosis Model
48. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
49. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction
50. On the future of thrombolytic therapy for acute myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.